| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 21, 2013Proven Lead Expands Access to MRI for Patients with Slow Heartbeat
TOLOCHENAZ - May 21, 2013 -- Medtronic today announced CE Mark (Conformité Européenne) and launch of its CapSureFix Novus(TM)5076 Lead, which is now approved in the EU for use in an MRI...
-
May 21, 2013Q4 Revenue of $4.5 Billion Grew 5% at Constant Currency; 4% as Reported
MINNEAPOLIS - May 21, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2013, which ended April 26, 2013. The Company reported worldwide...
-
May 20, 2013Backed by Robust Clinical Data on Broad Product Family, New Thrombus Removal System Offers Superior Deliverability
MINNEAPOLIS -- May 20, 2013 -- Expanding its portfolio of medical technology for the interventional treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT) announced today that the Export...
-
May 6, 2013Newly designed Devices Result in Fewer Hospitalizations for Patients, Deliver Increased Longevity, and Improved Comfort
MINNEAPOLIS - May 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of its newest cardiac devices: the Viva®portfolio of...
-
Apr 29, 2013
MEMPHIS, TENN. - April 29, 2013- Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology announced today the U.S. launch of several new product line additions to the VERTEX SELECT®...
-
Apr 29, 2013
MEMPHIS, TENN. - April 29, 2013- Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology announced today the global launch of the MAST ALIGNEDSM procedure. This comprehensive surgical...
-
Apr 4, 2013Distinguishing Features of New Accessory for Endovascular Interventions Include Optimal Seal for Superior Hemostasis and Reinforced Coil for Proven Kink Resistance
MINNEAPOLIS -- April 4, 2013 -- Complementing its market-leading portfolio of stent grafts for the endovascular repair of aortic aneurysms and related conditions, Medtronic, Inc. (NYSE: MDT)...
-
Mar 10, 201324-Month Clinical Update from Symplicity HTN-2 Presented Today at the 62nd Annual Scientific Session of the American College of Cardiology
MINNEAPOLIS and SAN FRANCISCO - March 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal...
-
Mar 7, 2013IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic's Rigorous Global Clinical Trial Program for Hypertension Treatment
MINNEAPOLIS - March 7, 2013 - Medtronic, Inc. (NYSE: MDT), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA)...
-
Mar 6, 2013FDA-CMS Parallel Review Program Designed to Enable Efficient and Earlier Patient Access to Innovative Medical Advancements
MINNEAPOLIS - March 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA)and the Centers for Medicare & Medicaid Services (CMS) have accepted the...